‹ Back
Cagrilintide and Semaglutide Blend
How it works
CagriSema opens two doors at once: amylin ends the meal through the brainstem fullness gate, and GLP-1 turns down hunger through the hypothalamus, so the effects add without doubling the sickness.
Sources
Read the original sources
- Development of cagrilintide, a long-acting amylin analogue, Kruse 2021, J Med Chem (Abstract · checked 2026-10-13)
- Amylinergic control of food intake in lean and obese rodents, Boyle 2011, Physiology and Behavior (Abstract · checked 2026-10-13)
- New pancreatic hormones: amylin, a literature review, 2014, Universum: Medicine and Pharmacology (Russia) (Summary · checked 2026-10-13)
- Discovery of the once-weekly GLP-1 analogue semaglutide, Lau 2015, J Med Chem (Abstract · checked 2026-10-13)
- Semaglutide lowers body weight in rodents via distributed neural pathways (2020 · Abstract; rodent mechanism · checked 2026-10-13)
- REDEFINE-1: cagrilintide with semaglutide (Garvey and colleagues · 2025 · Published abstract · checked 2026-10-08)
- Type 2 diabetes and obesity: the present and future of incretin therapy, Shestakova and Bashlykova 2025, Therapeutic Archive (Russia) (Summary · checked 2026-10-13)